Global private equity and venture capital news and research

Vatera Healthcare Partners leads $70m round for Melinta Therapeutics

10 Feb 2014

pharmaceutical 12_sqPharmaceutical company Melinta Therapeutics has raised $70m via its third round of funding, which was led by existing backer Vatera Healthcare Partners.

The company will use the funds to advance delafloxacin, a differentiated fluoroquinolone, through an ongoing Phase 3 study to the submission of a new drug application in late 2014.

Melinta added that the proceeds will also support delafloxacin’s two ongoing Phase 3 trials for the treatment of acute bacterial skin and skin structure infections and and the selection of lead candidates from its RX-04 research program.

Executive director of Vatera Tom Koestler said, “We have seen real progress in this exceptional management team’s advancement of delafloxacin in terms of both its R&D and commercial strategy.

“We are committed to continuing to support Melinta and fostering the company’s growth into a strong and successful company with the potential near-term approval and launch of delafloxacin in 2015 as the foundation of this success.”

Vatera’s other portfolio companies include Rib-X Pharmaceuticals, which raised a $67.5m Series 2 round in November 2012.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016